跳至主要内容
临床试验/NL-OMON39817
NL-OMON39817
已完成
2 期

Boosting oxytocin after trauma: The effects of intranasal oxytocin administration on emotional and motivational brain processes in PTSD - The effect of oxytocin in PTSD

Academisch Medisch Centrum0 个研究点目标入组 83 人待定

概览

阶段
2 期
干预措施
未指定
疾病 / 适应症
posttraumatic stress disorder (PTSD) and stress disorder
发起方
Academisch Medisch Centrum
入组人数
83
状态
已完成
最后更新
去年

概览

简要总结

暂无简介。

注册库
who.int
开始日期
待定
结束日期
2015年1月1日
最后更新
去年
研究类型
Observational invasive

研究者

入排标准

入选标准

  • \* Age 18 \* 65 years
  • \* Capable to read and comprehend the Dutch language
  • \* Eligibility for MRI (i.e. no metals, pacemakers or claustrophobia)
  • \* Exposed to a potentially traumatic event, according to PTSD A1 criterion in the DSM\-IV (minimal 1 month ago), quantified as a score of 1 or higher on the Life Events Checklist (LEC).
  • PTSD patients:
  • \* Current PTSD diagnosis
  • \* CAPS score \* 45
  • Traumatized healthy controls:
  • \* CAPS\-score \< 15

排除标准

  • \* Any severe or chronic systemic disease
  • \* Current psychotic, bipolar, substance\-related, severe personality disorder, or mental retardation
  • \* Current severe depressive disorder
  • \* Prominent current suicidal risk or homicidal ideation
  • \* Severe cognitive impairment or a history of organic mental disorder
  • \* History of neurological disorders (e.g., traumatic brain injury, seizure history)
  • \* Reports of ongoing traumatization (e.g., in case of partner violence as index adult trauma)
  • \* Evidence of clinically significant and unstable medical conditions in which OT administration is contra\-indicative such as cardiovascular, gastro\-intestinal, pulmonary, severe renal, endocrine or hematological disorders, glaucoma, history of epilepsy, or a stroke or myocardial infarction within the past year
  • \* Use of certain medication: prostaglandins, certain anti\-migraine medications (ergot alkaloids), ß\-adrenergic receptor\-blocking agents, systemic glucocorticoids and psychopharmacological medication.
  • \* Sensitivity or allergy for OT or its components (e.g. methylhydroxybenzoate and propylhydroxybenzoate)

结局指标

主要结局

未指定

相似试验